Detalhe da pesquisa
1.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Med
; 5(1): 42-61.e23, 2024 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-38181791
2.
Chimeric mRNA-based COVID-19 vaccine induces protective immunity against Omicron and Delta variants.
Mol Ther Nucleic Acids
; 30: 465-476, 2022 Dec 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36345542
3.
Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.
Sci Rep
; 12(1): 15517, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36109550
4.
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants.
Med
; 3(10): 705-721.e11, 2022 10 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36044897
5.
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19.
Med
; 5(2): 169-171, 2024 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38340710